Outlook Therapeutics, Inc. Common Stock
Here’s whether Outlook Therapeutics, Inc. Common Stock (OTLK) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+43.72% over 10 days); 3-month momentum positive (+246.7%). Concerns: RSI 88 — overbought, elevated pullback risk; weak 1-year return of -33.7%; declining volume on rally — weak conviction (0.75x 30d avg). Currently 64.0% off its 52-week high. Score: +2/7.
OTLK is in a confirmed uptrend, trading above both its 50-day ($0.41) and 200-day ($0.87) moving averages. With an RSI of 87.7, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -33.7% compares to +22.9% for SPY (trailed the market by 56.6%). The current 64.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.